


Resurrect Therapeutics, Inc. Sponsors 2026 WIN Symposium in Rhode Island, Showcases AI-Powered Drug Discovery Platform, and Receives Enthusiastic Response from Scientific Community

[Providence, Rhode Island, October 21, 2026] – Resurrect Therapeutics, Inc. an innovative biotechnology intelligence platform leveraging artificial intelligence to identify and evaluate opportunities to revive discontinued drug development programs, announced its participation as a sponsor of the 2026 WIN Symposium, held October 2–3, 2026 at the Rhode Island Convention Center in Providence, Rhode Island. The international symposium, themed “**Precision Oncology: Innovation and Equity Across the Globe,**” brought together leading clinicians, academic researchers, biotechnology executives, data scientists, and patient advocates and others to exchange ideas and advance innovation in personalized cancer medicine.



RESURRECT THERAPEUTICS

SYSTEMATIC IDENTIFICATION OF RECOVERABLE ONCOLOGY ASSETS HIDDEN AMONG TERMINATED CLINICAL PROGRAMS: TRANSFORMING DRUG ABANDONMENT INTO A SEARCHABLE SOURCE OF PRECISION THERAPEUTIC OPPORTUNITY.

Authors: James M. El-Deiry, JD, John R. El-Deiry, MBA, Wafik S. El-Deiry, MD, PhD, FACP

A TERMINATED TRIAL IS NOT NECESSARILY A FAILED DRUG.

THE PROBLEM

Why do clinical trials fail?

- "Business decision"
- "Strategic decision"
- "Sponsor decision"
- "Poor fit to patient population"
- "Lack of funding"
- "Administrative reasons"
- "Company restructuring"
- "Acquisition"
- "Program discontinued"
- "Study drug unavailable"
- "Commercial reasons"
- "Organizational reasons"
- "Investigator left"
- "Slow enrollment"
- "Poor results"
- "Insufficient recruitment"
- "Trial design failure"

Many trials fail for reasons other than safety and efficacy!

THE PLATFORM

We created a digital workflow that utilizes advanced data analysis to build an evidence-backed investigation around each discontinued asset, with recommended FDA-approval and commercialization paths.

DISCOVER → **INVESTIGATE** → **RESURRECT**

KEY SOURCES: NIH, PubMed, openFDA

PROPRIETARY ALGORITHM DESIGNED TO IDENTIFY, VALIDATE, LICENSE, AND ADVANCE HIGH-POTENTIAL THERAPEUTIC ASSETS TOWARD FDA APPROVAL AND COMMERCIALIZATION.

CASE STUDIES

1. **LMITK133** is a selective KRAS G12D inhibitor developed for treating advanced cancers harboring KRAS G12D mutations. Clinical development was discontinued before definitive efficacy evaluation, with publicly reported limitations centered on formulation and pharmacokinetic variability rather than target inhibition. The program therefore represents a precision oncology asset with strong biological rationale and a potentially addressable development barrier.
2. **TUR022** is a DDXIT1 pathway therapeutic with potential relevance to precision oncology through selective targeting of activated oncogenes in specific components of the cancer microenvironment. Its mechanism may be particularly relevant in treatment-resistant tumors where chronic remodeling and intracellular coordination strategies could improve therapeutic response.
3. **PF-04353806**, a CDK2 overexpression receptor antagonist, combined with standard first-line gemtuzumab-palladium in metastatic pancreatic cancer, was terminated by Pfizer as part of a 30-program portfolio sweep, with the sponsor explicitly stating in the regulatory that the decision was not due to safety or efficacy – a textbook company-level non-scientific stop with a published Phase IIb dataset already in hand.
4. **Velindre**, an inducible IL-12 expression construct, was halted for business reasons before its immunomodulatory hypothesis. In glioblastoma, it could be clinically tested, measuring a high-impact, organ-specific oncology asset whose exposure and biomarker strategy are tractable.

To learn more about these potentially recoverable assets, visit our website by scanning the QR code:

[resurrect-therapeutics.org](https://www.resurrect-therapeutics.org)

More Engaging Features: Biotech/Pharma News & Social Media Platform

Providence, RI

As a 2026 WIN Symposium Sponsor, Resurrect Therapeutics, Inc. introduced attendees to its AI-powered platform designed to identify promising therapeutic candidates that have been discontinued, deprioritized, or abandoned during clinical development. By integrating clinical trial data, scientific literature, and drug development intelligence, the platform effectively uncovers overlooked opportunities for further investigation, repurposing, licensing, renewed therapeutic development, and commercialization.


Resurrect Therapeutics received an enthusiastic response from 2026 WIN Symposium attendees, particularly students, academic scientists, and patient advocates. Participants expressed strong interest in the platform's potential to make valuable scientific information more accessible, accelerate therapeutic research, and help promising drug candidates to receive renewed consideration and accelerated development. Discussions throughout the WIN Symposium reflected considerable excitement about the opportunities artificial intelligence presents for advancing biomedical discovery.

“One of the most encouraging aspects of the symposium was the enthusiasm we received from students, scientists, and patient advocates who immediately recognized the possibilities of our platform,” said James El-Deiry, JD, Director at Resurrect Therapeutics who designed and developed the “*Resurrect Intelligence*” software. “Every year, promising therapeutic programs are discontinued for reasons that do not necessarily reflect a lack of scientific potential. We believe there is an enormous opportunity to revisit these programs, connect researchers with overlooked discoveries, and ultimately help bring more promising treatments to patients.”

In addition to the poster presentation at the 2026 WIN Symposium, Resurrect Therapeutics, Inc. staffed a display to demonstrate the “Resurrect Intelligence” software, the goals of Resurrect Therapeutics, and some of what it has uncovered that was presented in the poster for additional feedback, networking, and collaboration.



To encourage engagement and express appreciation to symposium participants, Resurrect Therapeutics also distributed \$25 Dunkin’ gift cards during the conference. The initiative contributed to a welcoming, interactive atmosphere and provided an opportunity to introduce participants to the platform and gather valuable feedback from the scientific community.



into meaningful therapeutic opportunities. In this photo, James El-Deiry is discussing future collaborations with leaders in Oncology in Shanghai and Guangzhou, China at the 2026 WIN Symposium Banquet at the Hope Club in Providence, RI on October 3, 2026.

The social events at the 2026 WIN Symposium provided the Resurrect Therapeutics’ team with valuable opportunities to engage with researchers, industry professionals, and patient advocates on the challenges of therapeutic development and the importance of preserving and building upon prior scientific investment. Resurrect Therapeutics’ participation reflects its commitment to fostering scientific collaboration, supporting the next generation of researchers, and accelerating the translation of biomedical discoveries

About Resurrect Therapeutics, Inc.

Resurrect Therapeutics is an AI-powered biotechnology intelligence and discovery platform dedicated to identifying and advancing opportunities to revive discontinued and overlooked therapeutic programs. The platform integrates clinical trial information, scientific publications, drug development histories, and artificial intelligence to help researchers, biotechnology companies, investors, and other stakeholders discover promising drug candidates and evaluate their potential for renewed development. Built on the principle that *a terminated clinical trial does not necessarily mean a failed drug*, Resurrect Therapeutics, Inc. seeks to unlock overlooked scientific value, encourage collaboration across the biotechnology ecosystem, and accelerate the development of potentially life-changing therapies.